Shape Therapeutics News Today

Two professors at the University of California San Diego Jacobs School of Engineering have been named 2023 Fellows of the National Academy of Inventors (NAI).Eric Fullerton, a professor in the Department of Electrical and Computer Engineering, and Pr

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco. The J.P. Morgan Healthcare Conference has...

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco.

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference in San...

<strong>The CEO of the controversial firm says the new service is possible to due its existing technology, plus increased capacity at the Wilsonville facility</strong>

BioPharma

To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.

In its second big pharma deal to date, Shape Therapeutics Inc. drew Otsuka Pharmaceutical Co. Ltd. to the table in a potential $1.5 billion-plus collaboration initially aimed at developing gene therapies for ocular diseases. The multitarget agreement, which includes options for additional targets and tissue types, will combine Shape’s AI-driven adeno-associated virus (AAV) platform and Otsuka’s expertise in ophthalmology to develop intravitreally delivered AAV therapies.

The Moderna COVID-19 vaccine was the ultimate home run for this biotech venture firm. It’s a tough act to follow.

Key trends include fewer and slower financings, a surge of decisive data readouts for cancer vaccines, and further development of mRNA, cell, and gene therapies.